Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform

Public Health

Volumn 120, Issue 11, 2006, Pages 1081-1087

  Agtini, M D ^a   Ochiai, R L ^b   Soeharno, R ^a   Lee, H J ^b   Sundoro, J ^c   Hadinegoro, S R ^d   Han, O P ^b   Tana, L ^a   Halim, F X S ^a   Ghani, L ^a   Delima, ^a   Lestari, W ^a   Sintawati, F X ^d   Kusumawardani, N ^a   Malik, R ^a   Santoso, T S ^a   Nadjib, M ^e   Soeroso, S ^c   Wangsasaputra, F ^a   Ali, M ^b   Ivanoff, B ^b,f   Galindo, C M ^b   Pang, T ^f   Clemens, J D ^b   Suwandono, A ^a   Acosta, C J ^b   more..

^a NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^b International Vaccine Institute   (South Korea)

^c MINISTRY OF HEALTH   (Indonesia)

^d National Adverse Event Following Immunization Monitoring Committee   (Indonesia)

^e UNIVERSITY OF INDONESIA   (Indonesia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Indonesia; Mass vaccination; Typhoid fever; Typhoid vi vaccine

Indexed keywords

TYPHERIX; TYPHOID VACCINE;

DISEASE CONTROL; HEALTH POLICY; IMMUNIZATION; PUBLIC HEALTH; TYPHOID; VACCINATION;

ARTICLE; ASTHENIA; CHILD; COUGHING; DIZZINESS; DRUG FEVER; DRUG SAFETY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INDONESIA; INFORMED CONSENT; MAJOR CLINICAL STUDY; NAUSEA; PATIENT MONITORING; PRIMARY SCHOOL; SIDE EFFECT; SINGLE DRUG DOSE; STUDENT; SWEATING; TYPHOID FEVER; VACCINATION; VOMITING;

ANTIGENS, BACTERIAL; CHILD; FEASIBILITY STUDIES; HUMANS; INDONESIA; MASS IMMUNIZATION; MASS VACCINATION; PILOT PROJECTS; POLYSACCHARIDES, BACTERIAL; PROGRAM EVALUATION; REFRIGERATION; SAFETY; SALMONELLA ENTERICA; SCHOOL HEALTH SERVICES; STUDENTS; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

ASIA; EURASIA; INDONESIA; JAKARTA; SOUTHEAST ASIA;

EID: 33750006583     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.puhe.2006.06.008     Document Type: Article

References (18)

1. Ministry of Health, Indonesia. Communicable disease control and environmental health. Sub directorate surveillance data RI. Indonesia Ministry of Health, Jakarta, 2003.
2. Robbins J.D., and Robbins J.B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 150 (1984) 436-449
3. Deroeck D., Clemens J.D., Nyamete A., and Mahoney R.T. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23 (2005) 2762-2774
4. Acosta C.J., Galindo C.M., Ochiai R.L., Danovaro-Holliday M.C., Page A.L., Vu D.T., et al. The role of epidemiology in the introduction of Vi polysaccharide typhoid fever vaccines in Asia. J Health Popul Nutr 22 (2004) 240-245
5. Acosta C.J., Galindo C.M., Ali M., Abu-Elyazeed R., Ochiai R.L., Danovaro-Holliday M.C., et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop Med Int Health 10 (2005) 1219-1228
6. Ministry of Health, Indonesia. North Jakarta district health profile. Indonesia Ministry of Health, Jakarta, 2002.
7. International Conference on Harmonisation (E6R1), 1996. Good clinical practice: consolidated guideline. Available from http://www.ich.org/LOB/media/MEDIA482.pdf (last accessed 15 June 2006).
8. Cordero-Yap L., Rivera R.G., Dispo A.P., and Mallabo J. Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years. BioDrugs 15 suppl 1 (2001) 27
9. GlaxoSmithKline Inc. Product monograph, Typherix TM: Salmonella Typhi Vi capsular polysaccharide vaccine (pamphlet), 2002.
10. Pelser H.H. Reactogenicity and immunogenicity of a single dose of typhoid Vi polysaccharide vaccine in children aged between 4 and 14 years. BioDrugs 15 (2001) 13-19
11. Ramkissoon A., and Jugnundan P. Reactogenicity and immunogenicity of a single dose of a typhoid Vi polysaccharide vaccine in adolescents. BioDrugs 15 suppl 1 (2001) 21-26
12. World Health Organization. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. WHO/EPI/TRAM/93.02 REV.1, Geneva, Switzerland, 1997.
13. Simms C., and Rowson M. Reassessment of health effects of the Indonesian economic crisis: donors versus the data. Lancet 361 (2003) 1382-1385
14. Kosen S. Study on safety of injection practices in immunization campaigns for children (BIAS), unpublished work.
15. Ministry of Health, Indonesia. National-level 5 year strategic plan for immunization services in Indonesia. Operational objectives. Indonesia Ministry of Health. Jakarta, 2001.
16. Begier E.M., Burwen D.R., Haber P., and Ball R. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis 38 (2004) 771-779
17. Klugman K.P., Koornhof H.J., Robbins J.B., and Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14 (1994) 435-438
18. Acosta C.J., Hong-Hui Y., Ning W., Qion G., Qun D., Xiaolei M., et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. Vaccine 23 48-49 (2005) 5618-5623